For research use only. Not for therapeutic Use.
Sipagladenant (Compound I) is an orally active adenosine receptor A2A inverse agonist[1]. Sipagladenant can be used in frontal lobe dysfunction research[2].
Sipagladenant (oral administration; 0.3 mg/kg; once) treatment improves cognitive impairment due to a decline in dopamine function in the medial prefrontal cortex[2].
Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve alternation behavior[2].
Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve gait parameters[2].
| Catalog Number | I043365 |
| CAS Number | 858979-50-7 |
| Synonyms | N-[4-(furan-2-yl)-5-(oxane-4-carbonyl)-1,3-thiazol-2-yl]-6-methylpyridine-3-carboxamide |
| Molecular Formula | C20H19N3O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C20H19N3O4S/c1-12-4-5-14(11-21-12)19(25)23-20-22-16(15-3-2-8-27-15)18(28-20)17(24)13-6-9-26-10-7-13/h2-5,8,11,13H,6-7,9-10H2,1H3,(H,22,23,25) |
| InChIKey | KMFLQPJJHQNKKF-UHFFFAOYSA-N |
| SMILES | CC1=NC=C(C=C1)C(=O)NC2=NC(=C(S2)C(=O)C3CCOCC3)C4=CC=CO4 |
| Reference | [1]. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf?sfvrsn=8544ca1e_3&download=true [2]. Horita, Takako. THERAPEUTIC AGENT FOR FRONTAL LOBE DYSFUNCTION, WO2016148308A1. |
